Biotech Values

[DewDiligence]

…whereas ABT-450 is just an important ingredient within a multi-drug oral combo.

If ABT-450 merely gets approved for marketing and then completely bombs in the commercial marketplace, ENTA will still earn pre-commercial milestone payments from ABBV that are roughly equal to ENTA’s current enterprise value.

Since antiviral drugs almost never fail in phase-3 for efficacy reasons, ENTA’s risk/reward tradeoff is favorably skewed at the current valuation to an uncommon degree.